Clin2
NCT07639840Possibly a fitNot yet recruiting

Roflumilast foam for skin rashes from cancer immunotherapy

Immune-related Dermatitis

Treatments studied

Part of Cancer, Immune system & allergy, Skin clinical trials.

This study tests whether a new foam treatment (roflumilast) can safely reduce skin rashes, itching, and other skin problems caused by checkpoint inhibitor cancer drugs. If you've developed these skin side effects from immunotherapy, this trial may help ease your symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
20 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 or older and can give informed consent
  • You are currently taking or took checkpoint inhibitor cancer drugs within the last 6 months
  • You have a skin rash, itching, blistering, or psoriasis-like rash caused by your cancer medication
  • You are willing to avoid steroid creams and certain other skin treatments for the first 2 weeks
  • You agree not to start new immune-suppressing drugs during the trial (unless your skin gets much worse)
  • You are in good enough health to participate (life expectancy at least 9 months, able to care for yourself)

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07683806Not yet recruiting· Phase 3
Roflumilast Foam for Seborrheic Dermatitis

This trial tests a medicated foam called roflumilast to treat seborrheic dermatitis, a skin condition that causes redness, itching, and flaking. It may help people who have moderate to severe symptoms on their face, scalp, or body.

Bengbu, Anhui
NCT07689188Not yet recruiting· Phase 2
Roflumilast foam for hidradenitis suppurativa

This trial tests a new foam containing roflumilast (a medicine that reduces inflammation) for people with hidradenitis suppurativa (HS). It aims to see if the foam can safely reduce painful lumps and improve HS symptoms.

Missouri City, Texas
NCT07297602Recruiting· Phase 2
Oral roflumilast for moderate to severe eczema in teens and adults

This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.

Al Mansurah, Dakahlia Governorate
NCT07543640Not yet recruiting· Phase 2
Roflumilast for Hard-to-Treat Skin Folds and Genital Psoriasis

This trial tests whether a medication called roflumilast can help psoriasis in skin folds (like armpits or groin) that hasn't improved with creams or ointments. Researchers want to see if this pill or oral treatment works better than standard care for these sensitive areas.

NCT07233291Recruiting· Phase 2
Roflumilast pills for moderate to severe psoriasis in adults

This study tests an oral medicine called roflumilast for adults with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective when taken by mouth, and you can join if you have not used other systemic treatments recently.

Al Mansurah, Dakahlia Governorate
NCT07105254Recruiting· Phase 2
Roflumilast foam study for children with vitiligo

This study tests a medicated foam (Roflumilast) in children with non-segmental vitiligo to see if it can improve skin color on the face and body. It is for patients aged 2 to 17 with small patches and at least some pigmented hair in the face patches.

Dallas, Texas

Hear when a new Immune-related Dermatitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.